

Kimmtrak® (tebentafusp-tebn) (Intravenous)

Document Number: IC-0658

Last Review Date: 11/04/2025

Date of Origin: 03/01/2022

Dates Reviewed: 03/2022, 07/2022, 11/2022, 01/2023, 11/2023, 11/2024, 11/2025

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 6 months (after the initial first three infusions).
- Renewal: Prior authorization validity may be renewed every 6 months thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 400 billable units every 28 days

III. Initial Approval Criteria ¹

Prior authorization validity is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Patient has received the first three infusions (i.e., Day 1, 8, 15) in an appropriate healthcare setting and did not experience Grade 2 or worse hypotension (i.e., hypotension requiring medical intervention); **AND**

Universal Criteria ¹

- Patient does not have a clinically significant cardiac disease or impaired cardiac function (i.e., congestive heart failure [NYHA grade \geq 2], uncontrolled hypertension or clinically significant arrhythmia requiring medical treatment, QT interval > 470 msec or congenital long QT syndrome, acute myocardial infarction or unstable angina pectoris < 6 months prior to start of therapy); **AND**
- Patient does not have symptomatic or untreated brain metastases; **AND**

Uveal Melanoma † ‡ ◊ ¹⁻⁵

- Patient has unresectable or metastatic disease; **AND**
- Patient has HLA-A*02:01 genotype positive disease as determined by a Food and Drug Administration (FDA) approved or Clinical Laboratory Improvement Amendments (CLIA) compliant test ◊

◊ If confirmed using an immunotherapy assay-<http://www.fda.gov/companiondiagnostics>

† FDA Approved Indication(s); ‡ Compendium Recommended Indication(s); Ⓞ Orphan Drug

IV. Renewal Criteria ¹

Prior authorization validity may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: persistent/severe cytokine release syndrome, severe dermatological reactions, severe elevated liver enzymes, etc.; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread

V. Dosage/Administration ¹

Indication	Dose
Uveal Melanoma	Administer Kimmtrak, intravenously, according to the following schedule: <ul style="list-style-type: none">• 20 mcg on Day 1• 30 mcg on Day 8• 68 mcg on Day 15, then• 68 mcg once every week thereafter Treat patients until unacceptable toxicity or disease progression occur.
<i>– Administer the first three infusions of Kimmtrak in an appropriate healthcare setting by intravenous infusion over 15-20 minutes. Monitor patients during the infusion and for at least 16 hours after the infusion is complete.</i>	
<i>– Patients must be euvolemic prior to initiating the infusions.</i>	
<i>– If the patient does not experience Grade 2 or worse hypotension (requiring medical intervention) during or after the third infusion, administer subsequent doses in an appropriate ambulatory care setting, and monitor patients for a minimum of 30 minutes following each of these infusions.</i>	

VI. Billing Code/Availability Information

HCPCS Code:

- J9274 – Injection, tebentafusp-tebn, 1 mcg; 1 billable unit = 1 mcg

NDC:

- Kimmtrak 100 mcg/0.5 mL solution in a single-dose vial: 80446-0401-xx

VII. References

1. Kimmtrak [package insert]. Conshohocken, PA; Immunocare, Ltd., June 2024. Accessed October 2025.

2. Nathan P, Hassel JC, Rutkowski P, et al; IMCgp100-202 Investigators. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) tebentafusp. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed September 2025.
4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma: Uveal Version 1.2025. National Comprehensive Cancer Network, 2025. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed September 2025.
5. Sacco JJ, Carvajal RD, Butler MO, et al; Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024 Jun 6;12(6):e009028. doi: 10.1136/jitc-2024-009028. PMID: 38844408; PMCID: PMC11163599.

Appendix A – Non-Quantitative Treatment Limitations (NQL) Factor Checklist

Non-quantitative treatment limitations (NQLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime’s assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	Yes: Consider for PA
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C69.30	Malignant neoplasm of unspecified choroid
C69.31	Malignant neoplasm of right choroid
C69.32	Malignant neoplasm of left choroid

C69.40	Malignant neoplasm of unspecified ciliary body
C69.41	Malignant neoplasm of right ciliary body
C69.42	Malignant neoplasm of left ciliary body
C69.60	Malignant neoplasm of unspecified orbit
C69.61	Malignant neoplasm of right orbit
C69.62	Malignant neoplasm of left orbit

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC